Version 2.36 of HDC Discover was rolled out to production on January 23rd, 2024. Please do not hesitate to contact our support email support@hdcbc.ca should you have any questions or comments about any of these changes.
What’s New?
- We are introducing two new chronic disease prevalence measures listed below for all EMRs:
| Measure | MOIS | OSCAR | Profile | Med Access | Med Access – Legacy | Wolf |
| Chronic disease prevalence – One or more | NEW | NEW | NEW | NEW | NEW | NEW |
| Chronic disease prevalence – Two or more | NEW | NEW | NEW | NEW | NEW | NEW |
Improvements
- Updates have been applied to this measure name and description for increased accuracy:
| Measure | New Measure Name | New Measure Description |
| Heart failure patients prescribed with ACE inhibitor or ARB in the past year | Heart failure patients prescribed a RAAS inhibitor in the past year | The percentage of active patients with Heart Failure (HF) (based on the problem list) that have had a coded prescription for a Renin-angiotensin-aldosterone system (RAAS) inhibitor (including ACE Inhibitors and Angiotensin II antagonists) in the past year recorded in the EMR. |
- “Hypertension” and “Mood Disorder” concepts
Following user feedback, we have refined our concepts related to “Hypertension” and “Mood Disorder” to enhance precision. Consequently, users of MOIS and Med Access may observe a decrease in the reported prevalence of Hypertension and Mood Disorder in their practice.
- Medication Prescribing Measures
We have improved our concepts related to Medication Prescribing measures to enhance precision. Consequently, users may observe a change in their Medication Prescribing measures.